SHAFTESBURY_PHARMACY_LIMI - Accounts

Company registration number 05467716 (England and Wales)
SHAFTESBURY PHARMACY LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021
PAGES FOR FILING WITH REGISTRAR
SHAFTESBURY PHARMACY LIMITED
COMPANY INFORMATION
Directors
Mrs L Thakerar
Mr D Thakerar
Company number
05467716
Registered office
Lynwood House
373-375 Station Road
Harrow
Middlesex
HA1 2AW
Accountants
RDP Newmans LLP
Lynwood House
373-375 Station Road
Harrow
Middlesex
HA1 2AW
Business address
6 Shaftesbury Parade
South Harrow
Middlesex
HA2 0AJ
SHAFTESBURY PHARMACY LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 7
SHAFTESBURY PHARMACY LIMITED
BALANCE SHEET
AS AT
31 DECEMBER 2021
31 December 2021
- 1 -
2021
2020
Notes
£
£
£
£
Fixed assets
Intangible assets
3
140,000
175,000
Tangible assets
4
26,106
14,939
166,106
189,939
Current assets
Stocks
90,135
106,492
Debtors
5
328,716
160,199
Cash at bank and in hand
187,678
508,486
606,529
775,177
Creditors: amounts falling due within one year
6
(382,450)
(665,425)
Net current assets
224,079
109,752
Total assets less current liabilities
390,185
299,691
Creditors: amounts falling due after more than one year
7
(103,148)
(214,039)
Provisions for liabilities
(4,231)
(1,949)
Net assets
282,806
83,703
Capital and reserves
Called up share capital
8
100
100
Profit and loss reserves
282,706
83,603
Total equity
282,806
83,703

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 31 December 2021 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

SHAFTESBURY PHARMACY LIMITED
BALANCE SHEET (CONTINUED)
AS AT
31 DECEMBER 2021
31 December 2021
- 2 -
The financial statements were approved by the board of directors and authorised for issue on 19 November 2022 and are signed on its behalf by:
Mrs L Thakerar
Mr D Thakerar
Director
Director
Company Registration No. 05467716
SHAFTESBURY PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021
- 3 -
1
Accounting policies
Company information

Shaftesbury Pharmacy Limited is a private company limited by shares incorporated in England and Wales. The registered office is Lynwood House, 373-375 Station Road, Harrow, Middlesex, HA1 2AW.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

1.3
Intangible fixed assets - goodwill

Goodwill represents the excess of the cost of acquisition of unincorporated businesses over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is considered to have a finite useful life and id amortised on a systematic basis over its expected life, which is 20 years.

If there is indication that there has been a significant charge in amortisation rate, useful life or residual value of an intangible asset, the amortisation is revised prospectively to reflect the new estimates.

1.4
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures and fittings
25% reducing balance
Computers
25% reducing balance
Motor vehicles
25% reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

SHAFTESBURY PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021
1
Accounting policies
(Continued)
- 4 -
1.5
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.6
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.7
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.8
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

SHAFTESBURY PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021
1
Accounting policies
(Continued)
- 5 -
1.9
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.10
Government grants

Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received.

 

A grant that specifies performance conditions is recognised in income when the performance conditions are met. Where a grant does not specify performance conditions it is recognised in income when the proceeds are received or receivable. A grant received before the recognition criteria are satisfied is recognised as a liability.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2021
2020
Number
Number
Total
13
15
SHAFTESBURY PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021
- 6 -
3
Intangible fixed assets
Goodwill
£
Cost
At 1 January 2021 and 31 December 2021
700,000
Amortisation and impairment
At 1 January 2021
525,000
Amortisation charged for the year
35,000
At 31 December 2021
560,000
Carrying amount
At 31 December 2021
140,000
At 31 December 2020
175,000
4
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 January 2021
228,210
Additions
19,870
At 31 December 2021
248,080
Depreciation and impairment
At 1 January 2021
213,271
Depreciation charged in the year
8,703
At 31 December 2021
221,974
Carrying amount
At 31 December 2021
26,106
At 31 December 2020
14,939
5
Debtors
2021
2020
Amounts falling due within one year:
£
£
Trade debtors
173,429
117,403
Other debtors
155,287
42,796
328,716
160,199
SHAFTESBURY PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021
- 7 -
6
Creditors: amounts falling due within one year
2021
2020
£
£
Bank loans
36,475
36,475
Trade creditors
297,686
492,617
Taxation and social security
(22,831)
35,755
Other creditors
71,120
100,578
382,450
665,425
7
Creditors: amounts falling due after more than one year
2021
2020
£
£
Bank loans and overdrafts
103,148
184,623
Other creditors
-
0
29,416
103,148
214,039

The aggregate amount of creditors for which security has been given, amounted to £139,623 (2020: £221,099).

8
Called up share capital
2021
2020
2021
2020
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of £1 each
100
100
100
100
9
Directors' transactions

Loans have been granted by the company to its directors as follows:

Description
% Rate
Opening balance
Amounts advanced
Interest charged
Amounts repaid
Closing balance
£
£
£
£
£
2.00
(38,156)
251,939
371
(102,129)
112,025
(38,156)
251,939
371
(102,129)
112,025

The loan was repaid in full on 31 March 2022.

2021-12-312021-01-01false21 November 2022CCH SoftwareCCH Accounts Production 2022.300No description of principal activityMrs L ThakerarMr D Thakerar054677162021-01-012021-12-3105467716bus:Director12021-01-012021-12-3105467716bus:Director22021-01-012021-12-3105467716bus:RegisteredOffice2021-01-012021-12-31054677162021-12-31054677162020-12-3105467716core:NetGoodwill2021-12-3105467716core:NetGoodwill2020-12-3105467716core:OtherPropertyPlantEquipment2021-12-3105467716core:OtherPropertyPlantEquipment2020-12-3105467716core:CurrentFinancialInstrumentscore:WithinOneYear2021-12-3105467716core:CurrentFinancialInstrumentscore:WithinOneYear2020-12-3105467716core:Non-currentFinancialInstrumentscore:AfterOneYear2021-12-3105467716core:Non-currentFinancialInstrumentscore:AfterOneYear2020-12-3105467716core:CurrentFinancialInstruments2021-12-3105467716core:CurrentFinancialInstruments2020-12-3105467716core:Non-currentFinancialInstruments2021-12-3105467716core:Non-currentFinancialInstruments2020-12-3105467716core:ShareCapital2021-12-3105467716core:ShareCapital2020-12-3105467716core:RetainedEarningsAccumulatedLosses2021-12-3105467716core:RetainedEarningsAccumulatedLosses2020-12-3105467716core:Goodwill2021-01-012021-12-3105467716core:FurnitureFittings2021-01-012021-12-3105467716core:ComputerEquipment2021-01-012021-12-3105467716core:MotorVehicles2021-01-012021-12-31054677162020-01-012020-12-3105467716core:NetGoodwill2020-12-3105467716core:NetGoodwill2021-01-012021-12-3105467716core:OtherPropertyPlantEquipment2020-12-3105467716core:OtherPropertyPlantEquipment2021-01-012021-12-3105467716core:WithinOneYear2021-12-3105467716core:WithinOneYear2020-12-3105467716bus:PrivateLimitedCompanyLtd2021-01-012021-12-3105467716bus:SmallCompaniesRegimeForAccounts2021-01-012021-12-3105467716bus:FRS1022021-01-012021-12-3105467716bus:AuditExemptWithAccountantsReport2021-01-012021-12-3105467716bus:FullAccounts2021-01-012021-12-31xbrli:purexbrli:sharesiso4217:GBP